Introduction

▼
Few data is available regarding medical expenditures associated with acute complications in patients with paediatric diabetes. In the U.S., expenditures were found to be mainly increased in patients with diabetic ketoacidotic events (DKA), in particular due to hospitalisation, with up to 2-fold higher costs [ 1 ] . In Germany, all patients with paediatric diabetes have extensive diabetes education, mainly performed as inpatient care in contrast to other countries [ 2 , 3 ] . The risk of DKA has been reported to be lower than in the U.S. [ 4 ] . We aimed to estimate the 1-year cumulative incidence of at least 1 DKA and analyse diff erences in medical expenditures between paediatric patients with diabetes with and without DKA in Germany ( • ▶ (CI 9 813-11 644), respectively, with largest diff erences for hospitalization costs (€ 693, € 4 145, € 8 092). Age-sex-diabetes duration-adjusted cost ratios for patients with 1, or ≥ 2 DKAs compared to patients without DKA were 2.2 (CI 2.1-2.3) and 3.6 (CI 3.1-4.1), respectively. Conclusions: In Germany, paediatric diabetic patients with DKA had up to 3.6-fold higher diabetes-related costs compared to those without DKA. This cost excess was higher compared to a U.S. study, however, the proportion of patients with DKA was much lower (3.8 % versus 14.9 %). The lower frequency of DKA in Germany may be due to a higher access to and utilization of diabetes education. Interventions should reduce DKA and resulting hospital admission in pediatric patients in order to reduce costs and improve quality of life. Costs were signifi cantly increased in patients with DKA. Total annual costs in patients without, with 1, or ≥ 2 DKAs were € 3 330 (3 292-3 368), € 6 935 (6 627-7 244), and € 10 728 (9 813-11 644), respectively, with largest diff erences for hospitalisation costs (€ 693, € 4 145, € 8 092). Cost ratios of total costs in patients with 1 or ≥ 2 DKAs compared to patients without DKA, adjusted for age, sex, and diabetes duration, were 2.2 (95 %-CI 2.1-2.3) and 3.6 (95 %-CI 3.1-4.1), respectively. Additional adjustment for migration background did not alter results.
Short Communication
Discussion
▼
Several limitations have to be considered. Our analysis was not population-based but represents the majority of German paediatric diabetes care facilities. As a consequence, the results of the study may not be representative for all patients with type 1 diabetes less than 20 years of age in Germany. However, the DPV documentation system is used in all kinds of medical facilities. Also, when comparing our study population with a populationbased cohort, course and outcomes of diabetes care have been shown to be very similar [ 3 ] . There may be some uncertainty in our cost estimation, e. g. we have applied the general items of the medical fee schedule for calculating outpatient care costs. However, we do not believe that this should have biased the association between DKA and costs. The strength of our study lies in using a comprehensive computer database containing data from continual, standardised documentation of routine care. Thus, our health care utilization data can be assumed to be rather valid and unbiased. Nevertheless, under-or overreporting cannot be excluded. On the other hand, many of the clinics use this documentation system for administrative purposes and regular data validity tests are being performed on the DPV data. Hence, we consider that our estimates are valid. Thus, in Germany, paediatric patients with DKA had up to 3.6-fold higher diabetes-related costs compared to those without DKA. This cost excess was much higher compared to the U.S. study [ 1 ] . In our study, the proportion of patients with DKA was much lower compared to the U.S. analysis (3.8 % vs. 14.9 %). The lower frequency of DKA in Germany may be due to a better and easier access to and higher utilisation of diabetes education. Increased hospitalisation and higher costs among patients sustaining DKA may be due to poor diabetes control. This hypothesis is supported by HbA1c values observed in patients without, with 1, or ≥ 2 DKAs (61 ± 9, 77 ± 3, 89 ± 4 mmol/mol, corresponding to 7.7 ± 1.3, 9.2 ± 1.9, and 10.3 ± 1.8 %, respectively). Intervention strategies should be developed to reduce DKA and resulting hospital admission in paediatric patients in order to reduce costs, but also improve quality of life. 
